サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：IBD（潰瘍性大腸炎・クローン病）治療薬の世界市場：業界分析、規模、シェア、成長、動向、予測（2022年～2031年）
市場調査レポート
商品コード
1121676

IBD（潰瘍性大腸炎・クローン病）治療薬の世界市場：業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

IBD [Ulcerative Colitis & Crohn's Disease] Treatment Market (Drug Class: TNF Inhibitors, Aminosalicylates, Integrin Antagonists, Corticosteroids, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 211 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.91円
IBD（潰瘍性大腸炎・クローン病）治療薬の世界市場：業界分析、規模、シェア、成長、動向、予測（2022年～2031年）
出版日: 2022年07月14日
発行: Transparency Market Research
ページ情報: 英文 211 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のIBD（潰瘍性大腸炎・クローン病）治療薬市場について調査分析し、市場の促進要因や抑制要因、機会、COVID-19の影響、セグメント別の分析と予測、地域別分析、企業プロファイルなどを提供しています。

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界のIBD（潰瘍性大腸炎・クローン病）治療薬市場

第4章 市場概要

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 世界のIBD（潰瘍性大腸炎・クローン病）治療薬の市場価値予測（2017年～2031年）

第5章 主な洞察

  • パイプライン分析
  • 主要な業界イベント
  • COVID-19流行による業界への影響（バリューチェーン、短・中・長期的な影響）

第6章 世界のIBD（潰瘍性大腸炎・クローン病）治療薬市場の分析と予測：医薬品クラス別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場価値予測：医薬品クラス別（2017年～2031年）
    • TNF阻害剤
    • アミノサリチル酸
    • インテグリン拮抗薬
    • コルチコステロイド
    • その他
  • 市場魅力分析：医薬品クラス別

第7章 世界のIBD（潰瘍性大腸炎・クローン病）治療薬市場の分析と予測：適応症別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場価値予測：適応症別（2017年～2031年）
    • 潰瘍性大腸炎
    • クローン病
  • 市場魅力分析：適応症別

第8章 世界のIBD（潰瘍性大腸炎・クローン病）治療薬市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場価値予測：流通チャネル別（2017年～2031年）
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場魅力分析：流通チャネル別

第9章 世界のIBD（潰瘍性大腸炎・クローン病）治療薬市場の分析と予測：地域別

  • 主な調査結果
  • 市場価値予測：地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析：地域別

第10章 北米のIBD（潰瘍性大腸炎・クローン病）治療薬市場の分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：医薬品クラス別（2017年～2031年）
    • TNF阻害剤
    • アミノサリチル酸
    • インテグリン拮抗薬
    • コルチコステロイド
    • その他
  • 市場価値予測：適応症別（2017年～2031年）
    • 潰瘍性大腸炎
    • クローン病
  • 市場価値予測：流通チャネル別（2017年～2031年）
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場価値予測：国別（2017年～2031年）
    • 米国
    • カナダ
  • 市場魅力分析
    • 医薬品クラス別
    • 適応症別
    • 流通チャネル別
    • 国別

第11章 欧州のIBD（潰瘍性大腸炎・クローン病）治療薬市場の分析と予測

第12章 アジア太平洋地域のIBD（潰瘍性大腸炎・クローン病）治療薬市場の分析と予測

第13章 ラテンアメリカのIBD（潰瘍性大腸炎・クローン病）治療薬市場の分析と予測

第14章 中東・アフリカのIBD（潰瘍性大腸炎・クローン病）治療薬市場の分析と予測

第15章 競合情勢

  • 市場参加者 - 競合マトリックス（階層・企業規模別）
  • 市場シェア分析：企業別（2021年）
  • 企業プロファイル
    • AbbVie, Inc.
    • Allergan plc
    • Bausch Health Companies, Inc.
    • Biogen, Inc.
    • Bristol-Myers Squibb Company
    • Celltrion Healthcare Co., Ltd.
    • Janssen Biotech, Inc. (Johnson & Johnson)
    • Novartis AG
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • UCB, Inc.
    • その他の有名企業
図表

List of Tables

  • Table 01: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 03: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 07: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 08: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 11: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 12: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 15: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 16: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 19: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 20: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 23: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 24: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Market Value Share, by Drug Class, 2021
  • Figure 03: Market Value Share, by Disease Indication, 2021
  • Figure 04: Market Value Share, by Distribution Channel, 2021
  • Figure 05: Market Value Share, by Region, 2021
  • Figure 06: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 07: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2022-2031
  • Figure 08: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by TNF Inhibitors, 2017-2031
  • Figure 09: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Aminosalicylates, 2017-2031
  • Figure 10: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Integrin Antagonists, 2017-2031
  • Figure 11: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2017-2031
  • Figure 12: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017-2031
  • Figure 13: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031
  • Figure 14: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2022-2031
  • Figure 15: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ulcerative Colitis, 2017-2031
  • Figure 16: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Crohn's Disease, 2017-2031
  • Figure 17: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 18: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2022-2031
  • Figure 19: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2017-2031
  • Figure 20: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2017-2031
  • Figure 21: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2017-2027
  • Figure 22: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Region, 2021 and 2031
  • Figure 23: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Region, 2022-2031
  • Figure 24: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2031
  • Figure 25: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 26: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 27: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 28: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031
  • Figure 29: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 30: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 31: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
  • Figure 32: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 33: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2031
  • Figure 34: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 35: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 36: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 37: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031
  • Figure 38: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 39: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 40: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
  • Figure 41: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 42: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 43: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Country/Sub-region, 2021 and 2031
  • Figure 44: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Country/Sub-region, 2022-2031
  • Figure 45: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 46: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031
  • Figure 47: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 48: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2022-2031
  • Figure 49: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2022-2031
  • Figure 50: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2022-2031
  • Figure 51: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2031
  • Figure 52: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 53: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
  • Figure 54: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 55: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031
  • Figure 56: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 57: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 58: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
  • Figure 59: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 60: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 61: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Country/Sub-region, 2021 and 2031
  • Figure 62: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Country/Sub-region, 2022-2031
  • Figure 63: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 64: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031
  • Figure 65: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 66: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2022-2031
  • Figure 67: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2022-2031
  • Figure 68: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2022-2031
目次
Product Code: TMRGL1473

The report provides revenue of the global IBD (Ulcerative Colitis & Crohn's Disease) treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global IBD (Ulcerative Colitis & Crohn's Disease) treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the IBD (Ulcerative Colitis & Crohn's Disease) treatment market.

The report delves into the competitive landscape of the global IBD (Ulcerative Colitis & Crohn's Disease) treatment market. Key players operating in the global IBD (Ulcerative Colitis & Crohn's Disease) treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global IBD (Ulcerative Colitis & Crohn's Disease) treatment market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

4. Market Overview

  • 4.1. Overview
  • 4.2. Market Dynamics
    • 4.2.1. Drivers
    • 4.2.2. Restraints
    • 4.2.3. Opportunities
  • 4.3. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Industry Events
  • 5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. TNF Inhibitors
    • 6.3.2. Aminosalicylates
    • 6.3.3. Integrin Antagonists
    • 6.3.4. Corticosteroids
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Disease Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 7.3.1. Ulcerative Colitis
    • 7.3.2. Crohn's Disease
  • 7.4. Market Attractiveness Analysis, by Disease Indication

8. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. TNF Inhibitors
    • 10.2.2. Aminosalicylates
    • 10.2.3. Integrin Antagonists
    • 10.2.4. Corticosteroids
    • 10.2.5. Others
  • 10.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 10.3.1. Ulcerative Colitis
    • 10.3.2. Crohn's Disease
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Disease Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. TNF Inhibitors
    • 11.2.2. Aminosalicylates
    • 11.2.3. Integrin Antagonists
    • 11.2.4. Corticosteroids
    • 11.2.5. Others
  • 11.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 11.3.1. Ulcerative Colitis
    • 11.3.2. Crohn's Disease
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Disease Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. TNF Inhibitors
    • 12.2.2. Aminosalicylates
    • 12.2.3. Integrin Antagonists
    • 12.2.4. Corticosteroids
    • 12.2.5. Others
  • 12.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 12.3.1. Ulcerative Colitis
    • 12.3.2. Crohn's Disease
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. India
    • 12.5.3. Japan
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Disease Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. TNF Inhibitors
    • 13.2.2. Aminosalicylates
    • 13.2.3. Integrin Antagonists
    • 13.2.4. Corticosteroids
    • 13.2.5. Others
  • 13.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 13.3.1. Ulcerative Colitis
    • 13.3.2. Crohn's Disease
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Disease Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. TNF Inhibitors
    • 14.2.2. Aminosalicylates
    • 14.2.3. Integrin Antagonists
    • 14.2.4. Corticosteroids
    • 14.2.5. Others
  • 14.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 14.3.1. Ulcerative Colitis
    • 14.3.2. Crohn's Disease
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Disease Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. AbbVie, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Allergan plc
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Bausch Health Companies, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Biogen, Inc.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Bristol-Myers Squibb Company
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Celltrion Healthcare Co., Ltd.
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Janssen Biotech, Inc. (Johnson & Johnson
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Novartis AG
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Pfizer, Inc.
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Takeda Pharmaceutical Company Limited
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview
    • 15.3.11. UCB, Inc.
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. SWOT Analysis
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Other Prominent Players